Nautilus Biotechnology Inc Financials

NAUT

Source SEC Filings (10-K/10-Q) Updated Feb 26, 2026 Currency USD FYE February

This page shows Nautilus Biotechnology Inc (NAUT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Nautilus Biotechnology Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Nautilus Biotechnology Inc generates $0.86 in operating cash flow (-$50.7M OCF vs -$59.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

-$52.0M

YoY+15.2%

Nautilus Biotechnology Inc generated -$52.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 15.2% from the prior year.

Net Income

-$59.0M

YoY+16.6%

Nautilus Biotechnology Inc reported -$59.0M in net income in fiscal year 2025. This represents an increase of 16.6% from the prior year.

EPS (Diluted)

$-0.47

YoY+16.1%

Nautilus Biotechnology Inc earned $-0.47 per diluted share (EPS) in fiscal year 2025. This represents an increase of 16.1% from the prior year.

Cash & Debt

$12.4M

YoY-55.2%

5Y CAGR-19.5%

Nautilus Biotechnology Inc held $12.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

127M

YoY+0.4%

Nautilus Biotechnology Inc had 127M shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$41.1M

YoY-18.6%

5Y CAGR+27.0%

Nautilus Biotechnology Inc invested $41.1M in research and development in fiscal year 2025. This represents a decrease of 18.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.3M

YoY-39.8%

5Y CAGR+6.8%

Nautilus Biotechnology Inc invested $1.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.8% from the prior year.

NAUT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$41.1M-18.6%	$50.5M+6.8%	$47.3M+25.4%	$37.7M+28.3%	$29.4M+136.1%	$12.4M
SG&A Expenses	$25.7M-17.0%	$31.0M+7.3%	$28.9M+11.4%	$25.9M+22.7%	$21.1M+538.5%	$3.3M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$59.0M+16.6%	-$70.8M-11.2%	-$63.7M-9.9%	-$57.9M-15.1%	-$50.3M-222.1%	-$15.6M
EPS (Diluted)	$-0.47+16.1%	$-0.56-9.8%	$-0.51-10.9%	$-0.46+23.3%	$-0.60	$-0.54

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.6M-7.6%	$10.4M-9.9%	$11.5M	N/A	$12.3M-1.2%	$12.4M-3.8%	$12.9M	N/A
SG&A Expenses	$5.9M-12.5%	$6.7M-8.3%	$7.3M	N/A	$6.8M-18.4%	$8.4M-3.7%	$8.7M	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$13.6M+9.7%	-$15.0M+9.5%	-$16.6M	N/A	-$16.4M+8.7%	-$18.0M+3.8%	-$18.7M	N/A
EPS (Diluted)	$-0.11+8.3%	$-0.12+7.7%	$-0.13	N/A	$-0.13+7.1%	$-0.14+6.7%	$-0.15	N/A

NAUT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$191.1M-21.3%	$242.7M-20.6%	$305.6M-12.7%	$350.1M-12.1%	$398.4M+368.7%	$85.0M
Current Assets	$106.0M-20.2%	$132.8M-24.9%	$176.8M-5.5%	$187.2M-46.4%	$349.2M+349.7%	$77.7M
Cash & Equivalents	$12.4M-55.2%	$27.6M+42.5%	$19.4M-83.1%	$114.5M-38.3%	$185.6M+407.1%	$36.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$34.1M+0.4%	$34.0M-15.4%	$40.2M+14.5%	$35.1M+0.7%	$34.9M-69.6%	$114.7M
Current Liabilities	$8.0M+4.2%	$7.6M-16.3%	$9.1M+34.3%	$6.8M+16.8%	$5.8M+92.6%	$3.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$157.0M-24.8%	$208.7M-21.3%	$265.4M-15.7%	$314.9M-13.4%	$363.6M+1323.3%	-$29.7M
Retained Earnings	-$332.0M-21.6%	-$273.0M-35.0%	-$202.2M-46.0%	-$138.6M-71.8%	-$80.6M-165.9%	-$30.3M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$200.9M-5.8%	$213.2M-6.4%	$227.7M-6.2%	$242.7M-6.5%	$259.7M-4.8%	$272.7M-5.5%	$288.6M-5.5%	$305.6M
Current Assets	$134.3M-10.9%	$150.7M+6.4%	$141.6M+6.6%	$132.8M-7.9%	$144.2M-15.6%	$170.9M-7.7%	$185.1M+4.7%	$176.8M
Cash & Equivalents	$23.9M-30.7%	$34.5M+3.7%	$33.2M+20.2%	$27.6M+527.0%	$4.4M-82.3%	$24.9M-3.3%	$25.7M+32.6%	$19.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$31.8M-1.0%	$32.1M-3.5%	$33.3M-2.2%	$34.0M-6.2%	$36.3M-3.2%	$37.5M-4.3%	$39.2M-2.6%	$40.2M
Current Liabilities	$9.0M+10.4%	$8.1M-0.2%	$8.2M+6.9%	$7.6M-11.9%	$8.7M-0.2%	$8.7M-5.8%	$9.2M+1.0%	$9.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$169.1M-6.6%	$181.1M-6.9%	$194.4M-6.8%	$208.7M-6.6%	$223.4M-5.0%	$235.3M-5.7%	$249.5M-6.0%	$265.4M
Retained Earnings	-$318.2M-4.5%	-$304.7M-5.2%	-$289.6M-6.1%	-$273.0M-6.9%	-$255.4M-6.9%	-$239.0M-8.2%	-$221.0M-9.3%	-$202.2M

NAUT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$50.7M+14.3%	-$59.1M-14.4%	-$51.7M-12.9%	-$45.8M-16.7%	-$39.2M-180.4%	-$14.0M
Capital Expenditures	$1.3M-39.8%	$2.1M-13.1%	$2.4M+5.1%	$2.3M+2.4%	$2.3M+146.4%	$921K
Free Cash Flow	-$52.0M+15.2%	-$61.3M-13.1%	-$54.2M-12.5%	-$48.1M-15.9%	-$41.5M-178.3%	-$14.9M
Investing Cash Flow	$35.2M-46.8%	$66.3M+251.5%	-$43.7M-69.9%	-$25.7M+81.5%	-$139.0M-449.7%	-$25.3M
Financing Cash Flow	$214K-81.3%	$1.1M+210.9%	$368K-34.5%	$562K-99.8%	$327.4M+331.4%	$75.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$11.0M+17.3%	-$13.3M+4.2%	-$13.9M+2.6%	-$14.3M-9.1%	-$13.1M+15.2%	-$15.5M+5.0%	-$16.3M-17.0%	-$13.9M
Capital Expenditures	$418K+5.6%	$396K+80.8%	$219K-13.8%	$254K-64.2%	$709K+38.5%	$512K-20.9%	$647K+56.7%	$413K
Free Cash Flow	-$11.5M+16.7%	-$13.7M+2.9%	-$14.2M+2.8%	-$14.6M-5.4%	-$13.8M+13.4%	-$16.0M+5.6%	-$16.9M-18.2%	-$14.3M
Investing Cash Flow	$452K-96.9%	$14.5M-25.8%	$19.5M-47.4%	$37.1M+594.5%	-$7.5M-152.5%	$14.3M-36.1%	$22.4M+154.4%	-$41.1M
Financing Cash Flow	$0-100.0%	$95K+427.8%	$18K-95.9%	$440K+214.3%	$140K-56.1%	$319K+30.2%	$245K-3.2%	$253K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NAUT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-30.9%-1.7pp	-29.2%-8.3pp	-20.8%-4.3pp	-16.6%-3.9pp	-12.6%+5.7pp	-18.4%
Current Ratio	13.33-4.1	17.40-2.0	19.39-8.2	27.57-32.5	60.09+34.4	25.73
Debt-to-Equity	0.22+0.1	0.16+0.0	0.15+0.0	0.11+0.0	0.10+4.0	-3.86
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-6.8%+0.3pp	-7.0%+0.3pp	-7.3%	N/A	-6.3%+0.3pp	-6.6%-0.1pp	-6.5%	N/A
Current Ratio	14.95-3.6	18.52+1.2	17.36-0.0	17.40+0.8	16.65-3.0	19.69-0.4	20.09+0.7	19.39
Debt-to-Equity	0.19+0.0	0.180.0	0.170.0	0.160.0	0.160.0	0.160.0	0.160.0	0.15
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Immunoprecise IPA

$95.5M

Champions Oncolo CSBR

$83.2M

Quince QNCX

$7.7M

Seer, Inc. SEER

$117.0M

eXoZymes Inc EXOZ

$74.8M

Frequently Asked Questions

Is Nautilus Biotechnology Inc profitable?

No, Nautilus Biotechnology Inc (NAUT) reported a net income of -$59.0M in fiscal year 2025.

What is Nautilus Biotechnology Inc's earnings per share (EPS)?

Nautilus Biotechnology Inc (NAUT) reported diluted earnings per share of $-0.47 for fiscal year 2025. This represents a 16.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Nautilus Biotechnology Inc's free cash flow?

Nautilus Biotechnology Inc (NAUT) generated -$52.0M in free cash flow during fiscal year 2025. This represents a 15.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nautilus Biotechnology Inc's operating cash flow?

Nautilus Biotechnology Inc (NAUT) generated -$50.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Nautilus Biotechnology Inc's total assets?

Nautilus Biotechnology Inc (NAUT) had $191.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nautilus Biotechnology Inc's capital expenditures?

Nautilus Biotechnology Inc (NAUT) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Nautilus Biotechnology Inc spend on research and development?

Nautilus Biotechnology Inc (NAUT) invested $41.1M in research and development during fiscal year 2025.

How many shares does Nautilus Biotechnology Inc have outstanding?

Nautilus Biotechnology Inc (NAUT) had 127M shares outstanding as of fiscal year 2025.

What is Nautilus Biotechnology Inc's current ratio?

Nautilus Biotechnology Inc (NAUT) had a current ratio of 13.33 as of fiscal year 2025, which is generally considered healthy.

What is Nautilus Biotechnology Inc's debt-to-equity ratio?

Nautilus Biotechnology Inc (NAUT) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nautilus Biotechnology Inc's return on assets (ROA)?

Nautilus Biotechnology Inc (NAUT) had a return on assets of -30.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Nautilus Biotechnology Inc's cash runway?

Based on fiscal year 2025 data, Nautilus Biotechnology Inc (NAUT) had $12.4M in cash against an annual operating cash burn of $50.7M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Nautilus Biotechnology Inc's Piotroski F-Score?

Nautilus Biotechnology Inc (NAUT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nautilus Biotechnology Inc's earnings high quality?

Nautilus Biotechnology Inc (NAUT) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.